Madrigal Pharmaceuticals Stock Forecast, Price & News

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

Is Madrigal Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

How has Madrigal Pharmaceuticals' stock been impacted by COVID-19?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MDGL stock has decreased by 22.3% and is now trading at $63.00.
View which stocks have been most impacted by COVID-19.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Madrigal Pharmaceuticals.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) EPS for the quarter, topping the consensus estimate of ($3.87) by $0.08.
View Madrigal Pharmaceuticals' earnings history.

What price target have analysts set for MDGL?

8 brokerages have issued 1-year target prices for Madrigal Pharmaceuticals' shares. Their forecasts range from $111.00 to $219.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $177.57 in the next twelve months. This suggests a possible upside of 181.9% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:

• Paul A. Friedman, Chairman, President & Chief Executive Officer
• Alex G. Howarth, Chief Financial Officer
• Rebecca A. Taub, Director & President-Research & Development
• Brian J. Lynch, Senior Vice President & General Counsel
• Remy Sukhija, Chief Commercial Officer & Senior Vice President

Who are some of Madrigal Pharmaceuticals' key competitors?

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Exelixis (EXEL).
View all of MDGL's competitors.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Shikiar Asset Management Inc. (0.06%), Liberty One Investment Management LLC (0.01%) and Cutler Group LP (0.00%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

Which major investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc..
View insider buying and selling activity for Madrigal Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC, and Cutler Group LP.
View insider buying and selling activity for Madrigal Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $63.00.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals has a market capitalization of $1.08 billion. The biopharmaceutical company earns $-202.24 million in net income (profit) each year or ($14.65) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 42 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Where are Madrigal Pharmaceuticals' headquarters?

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at [email protected], or via fax at 781-274-8228.